Hennersdorf Marcus G, Perings Stefan M, Zühlke Christian, Heidland Ulrich E, Perings Christian, Heintzen Matthias P, Strauer Bodo E
Department of Cardiology, Pneumology, and Angiology, Medical Clinic and Policlinic B, Heinrich Heine University, Moorenstrasse 5, Düsseldorf, Germany.
Intensive Care Med. 2002 Jul;28(7):925-9. doi: 10.1007/s00134-002-1317-3. Epub 2002 May 9.
To evaluate whether ibutilide can convert atrial fibrillation or flutter in patients in whom amiodarone has failed.
Clinical study in a university hospital intensive care unit (ICU).
Twenty-six patients were studied, in whom atrial fibrillation or flutter persisted for a maximum of 6 h at maximum. Patients were monitored continuously during the arrhythmia. Medical conversion was necessary due to symptomatic or hemodynamic causes.
All patients initially received amiodarone (150 mg i.v.) and after 2 h of persistent arrhythmia ibutilide (1 mg or, without success and body weight > 70 kg, 2 mg i.v.). Before the administration of ibutilide 1 g magnesium was administered, and high normal levels of potassium serum levels were achieved (4.5-5.0 mmol/l). RESULTS. After amiodarone atrial flutter persisted in 73% and atrial fibrillation in 27% of patients. After ibutilide the QT interval was prolonged from 327 +/- 61 to 387 +/- 62 ms. The QTc interval increased from 456 +/-32 to 461 +/- 66 ms. Conversion to normal sinus rhythm was achieved in 22 of 27 of cases. Nonsustained torsade de pointes tachycardia was seen in three patients (11%). No patient showed sustained ventricular tachycardia. Patients with proarrhythmic effects were characterized by a decreased left ventricular function.
In ICU patients ibutilide led to conversion to sinus rhythm in 81.5% of patients in whom amiodarone was unsuccessful. Nonsustained tachycardias were seen in 11%; sustained ventricular tachycardia was not seen. Ibutilide seems to be well suitable for conversion of recent onset atrial fibrillation or flutter and had no severe side effects in this study population.
评估伊布利特能否使胺碘酮治疗无效的患者的房颤或房扑转复。
在大学医院重症监护病房(ICU)进行的临床研究。
对26例患者进行了研究,这些患者的房颤或房扑持续时间最长为6小时。心律失常期间对患者进行持续监测。因症状性或血流动力学原因需要进行药物转复。
所有患者最初接受胺碘酮(静脉注射150mg),在心律失常持续2小时后给予伊布利特(静脉注射1mg,若未成功且体重>70kg,则静脉注射2mg)。在给予伊布利特之前,先给予1g镁,并使血清钾水平达到高正常水平(4.5 - 5.0mmol/L)。结果。给予胺碘酮后,73%的患者房扑持续,27%的患者房颤持续。给予伊布利特后,QT间期从327±61延长至387±62ms。QTc间期从456±32增加至461±66ms。27例患者中有22例转复为正常窦性心律。3例患者(11%)出现非持续性尖端扭转型室性心动过速。无患者出现持续性室性心动过速。有促心律失常作用的患者的特征是左心室功能降低。
在ICU患者中,伊布利特使81.5%胺碘酮治疗无效的患者转复为窦性心律。11%的患者出现非持续性心动过速;未观察到持续性室性心动过速。伊布利特似乎非常适合转复近期发作的房颤或房扑,且在本研究人群中无严重副作用。